IL217915A0 - Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors - Google Patents

Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors

Info

Publication number
IL217915A0
IL217915A0 IL217915A IL21791512A IL217915A0 IL 217915 A0 IL217915 A0 IL 217915A0 IL 217915 A IL217915 A IL 217915A IL 21791512 A IL21791512 A IL 21791512A IL 217915 A0 IL217915 A0 IL 217915A0
Authority
IL
Israel
Prior art keywords
astrocytes
inhibitors
treatment
tumor cells
endothelin receptors
Prior art date
Application number
IL217915A
Other languages
English (en)
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL217915(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of IL217915A0 publication Critical patent/IL217915A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
IL217915A 2009-08-10 2012-02-02 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors IL217915A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23268709P 2009-08-10 2009-08-10
PCT/US2010/044832 WO2011019630A2 (en) 2009-08-10 2010-08-09 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors

Publications (1)

Publication Number Publication Date
IL217915A0 true IL217915A0 (en) 2012-03-29

Family

ID=42938154

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217915A IL217915A0 (en) 2009-08-10 2012-02-02 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors

Country Status (27)

Country Link
US (2) US8999934B2 (OSRAM)
EP (1) EP2464218B1 (OSRAM)
JP (1) JP2013501791A (OSRAM)
KR (1) KR20120088665A (OSRAM)
CN (1) CN102510719B (OSRAM)
AU (1) AU2010282744B2 (OSRAM)
BR (1) BR112012003103A2 (OSRAM)
CA (1) CA2770397A1 (OSRAM)
CL (1) CL2012000333A1 (OSRAM)
DK (1) DK2464218T3 (OSRAM)
EA (1) EA023864B1 (OSRAM)
ES (1) ES2543280T3 (OSRAM)
HR (1) HRP20150890T1 (OSRAM)
HU (1) HUE026005T2 (OSRAM)
IL (1) IL217915A0 (OSRAM)
IN (1) IN2012DN01261A (OSRAM)
MA (1) MA33571B1 (OSRAM)
MX (1) MX2012001562A (OSRAM)
NZ (1) NZ598078A (OSRAM)
PL (1) PL2464218T3 (OSRAM)
PT (1) PT2464218E (OSRAM)
SG (1) SG178828A1 (OSRAM)
SI (1) SI2464218T1 (OSRAM)
TN (1) TN2012000054A1 (OSRAM)
TW (1) TWI483938B (OSRAM)
WO (1) WO2011019630A2 (OSRAM)
ZA (1) ZA201200980B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34952B1 (fr) * 2011-02-04 2014-03-01 Actelion Pharmaceuticals Ltd Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme
CN103796680A (zh) 2011-06-21 2014-05-14 约翰霍普金斯大学 用于增强针对赘生物的基于免疫的治疗的聚焦放射
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
JP6904570B2 (ja) * 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
CA2991059C (en) 2015-07-13 2024-01-16 Beyondspring Pharmaceuticals, Inc. Plinabulin monohydrate polymorphs
MX2018001507A (es) 2015-08-03 2018-09-18 Enb Therapeutics Llc Composiciones y metodos para tratar cánceres asociados con la activacion del etbr.
JP6996728B2 (ja) * 2016-01-07 2022-01-17 学校法人自治医科大学 グルコーストランスポーター１発現用アデノ随伴ウイルスベクター
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
IL268305B2 (en) 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
WO2018152340A1 (en) 2017-02-15 2018-08-23 The Regents Of The University Of California Compositions and methods for activating nk cells
JP7539151B2 (ja) 2018-01-12 2024-08-23 イーエヌビー・セラピューティクス・インク Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
CN109232546B (zh) 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
JP2022533237A (ja) 2019-05-22 2022-07-21 シージャーヂュアン・サガシティー・ニュー・ドラッグ・デヴェロップメント・カンパニー・リミテッド ピリミジンスルホンアミド系化合物の結晶形及びその製造方法
CN112062857B (zh) * 2019-06-10 2024-08-09 鸿运华宁（杭州）生物医药有限公司 Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155805A0 (en) 2000-12-18 2003-12-23 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
HRP20120957T1 (hr) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmaceutski sastav koji sadrži pirimidin-sulfamid
CA2714608A1 (en) 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Combination comprising paclitaxel for treating ovarian cancer
MA34952B1 (fr) 2011-02-04 2014-03-01 Actelion Pharmaceuticals Ltd Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme

Also Published As

Publication number Publication date
ES2543280T3 (es) 2015-08-17
JP2013501791A (ja) 2013-01-17
NZ598078A (en) 2013-07-26
PT2464218E (pt) 2015-09-16
ZA201200980B (en) 2012-10-31
EP2464218B1 (en) 2015-05-27
HRP20150890T1 (hr) 2015-09-25
TN2012000054A1 (en) 2013-09-19
PL2464218T3 (pl) 2015-12-31
WO2011019630A2 (en) 2011-02-17
SG178828A1 (en) 2012-04-27
TW201109315A (en) 2011-03-16
CN102510719B (zh) 2015-07-22
WO2011019630A3 (en) 2011-06-03
AU2010282744B2 (en) 2014-08-28
MX2012001562A (es) 2013-01-29
CA2770397A1 (en) 2011-02-17
BR112012003103A2 (pt) 2016-04-19
HUE026005T2 (en) 2016-04-28
CN102510719A (zh) 2012-06-20
CL2012000333A1 (es) 2013-01-25
SI2464218T1 (sl) 2015-10-30
KR20120088665A (ko) 2012-08-08
HK1171336A1 (en) 2013-03-28
US20120144510A1 (en) 2012-06-07
US20150352113A1 (en) 2015-12-10
EA023864B1 (ru) 2016-07-29
US8999934B2 (en) 2015-04-07
TWI483938B (zh) 2015-05-11
AU2010282744A1 (en) 2012-03-22
MA33571B1 (fr) 2012-09-01
EP2464218A2 (en) 2012-06-20
EA201270264A1 (ru) 2013-02-28
IN2012DN01261A (OSRAM) 2015-05-15
DK2464218T3 (en) 2015-07-20

Similar Documents

Publication Publication Date Title
IL217915A0 (en) Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors
ZA201700326B (en) Inhibitors of beta-secretase
EP2401357A4 (en) HOST CELLS AND METHOD FOR THEIR USE
ZA201008392B (en) Treatment of pluripotent cells
PL2448938T3 (pl) Pirymidynony jako inhibitory PI3K
GB0911566D0 (en) T cell receptors
ZA201005236B (en) Electrode and electrode coating
EP2580352A4 (en) WAY CHARACTERIZATION OF CELLS
EP2438246A4 (en) CONSTRUCTION ASPECTS
ZA201206456B (en) Uses of dgati inhibitors
GB0915515D0 (en) Treatment of vasculoproliferative conditions
SI2506840T1 (sl) Uporabe zaviralcev faktorja, ki jih inducira hiposkija
PL2393919T3 (pl) Nowa ciągła ludzka linia komórkowa
EP2496230A4 (en) INHIBITORS OF IRE-1 ALPHA
EP2455088A4 (en) INHIBITOR OF LIFT OF TRIGLYCERIDE RATE IN BLOOD
IL217756A0 (en) Inhibitors of jnk
EP2398484A4 (en) Inhibition of multiple cell activation signals
FI20095792L (fi) Ihmissolujen käyttö
TWM372743U (en) Improved structure of Kendama
TWM365675U (en) Improved structure of teapoy
GB0908609D0 (en) New use of isoQC inhibitors
IL200674A0 (en) Solar arrangement and method of use
TWM372203U (en) Structure of goggles
TWM374127U (en) Structure of three-string Huqin
GB201012495D0 (en) Targeted differntiation of stem cells